Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes (2021)

First Author: Garcia-Manero G

Attributed to: Transcriptional Regulation of GATA-1 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1200/JCO.20.02619

PubMed Identifier: 33764805

Publication URI: http://europepmc.org/abstract/MED/33764805

Type: Journal Article/Review

Parent Publication: Journal of Clinical Oncology

Issue: 13

ISSN: 0732-183X